Inhibition of glioblastoma cell proliferation, migration and invasion by the proteasome antagonist carfilzomib.

about

Cannabinoids synergize with carfilzomib, reducing multiple myeloma cells viability and migration.

P2860

Q42314593-CA9033BF-ACD4-4C7F-9DB4-B74C656D7F7F

P2860

Inhibition of glioblastoma cell proliferation, migration and invasion by the proteasome antagonist carfilzomib.

Item

http://www.wikidata.org/entity/Q38776733

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Inhibition of glioblastoma cel ...... easome antagonist carfilzomib.

@en

type

Item

label

Inhibition of glioblastoma cel ...... easome antagonist carfilzomib.

@en

prefLabel

Inhibition of glioblastoma cel ...... easome antagonist carfilzomib.

@en

P1476

Inhibition of glioblastoma cel ...... teasome antagonist carfilzomib

@en

P2093

Bo Li

http://www.w3.org/2001/XMLSchema#string

Lipi Shukla

http://www.w3.org/2001/XMLSchema#string

Lucia Paradiso

http://www.w3.org/2001/XMLSchema#string

Nicole C Harris

http://www.w3.org/2001/XMLSchema#string

Ramin Shayan

http://www.w3.org/2001/XMLSchema#string

Thomas M B Ware

http://www.w3.org/2001/XMLSchema#string

Zammam Areeb

http://www.w3.org/2001/XMLSchema#string

P2860

Bortezomib primes glioblastoma, including glioblastoma stem cells, for TRAIL by increasing tBid stability and mitochondrial apoptosis

Challenges to targeting epidermal growth factor receptor in glioblastoma: escape mechanisms and combinatorial treatment strategies

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

New functions for the matrix metalloproteinases in cancer progression

Recent developments in the use of chemotherapy in brain tumours.

Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme.

Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02).

Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study

P2888

s12032-016-0767-3

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12032-016-0767-3

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-04-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1042628761

http://www.w3.org/2001/XMLSchema#string

P698

27098175

http://www.w3.org/2001/XMLSchema#string

Inhibition of glioblastoma cell proliferation, migration and invasion by the proteasome antagonist carfilzomib.

about

P2860

P2860

Inhibition of glioblastoma cell proliferation, migration and invasion by the proteasome antagonist carfilzomib.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698